糖皮质激素受体表达与侵袭性原发性子宫内膜癌相关,且从原发灶到转移灶表达升高
该研究采用免疫组化检测724例原发肿瘤和289例转移灶(来自135例患者)中糖皮质激素受体(GR)的表达,探讨其与临床病理变量及生存的关系。结果显示GR表达在非子宫内膜样肿瘤中显著高于子宫内膜样肿瘤,与侵袭性疾病标志物及不良生存相关;激素受体阴性亚组中GR高表达与疾病特异性生存差高度显著相关;从原发灶到转移灶GR表达总体升高。
要点
- 非子宫内膜样肿瘤的GR表达显著高于子宫内膜样肿瘤
- GR表达与侵袭性疾病标志物及不良生存相关,多因素分析校正年龄、FIGO分期和组织学分级后仍显著
- 激素受体阴性亚组中GR高表达与疾病特异性生存差高度显著相关
核心结论
- 原发性子宫内膜癌中GR表达与侵袭性疾病和不良生存相关。
- 多数转移性子宫内膜癌病灶表达GR,GR可能成为预后不良早期及转移性子宫内膜癌辅助治疗的治疗靶点。
研究设计与样本
- 采用免疫组化(IHC)检测724例原发肿瘤和289例转移灶(来自135例患者)中GR的表达,并分析其与临床病理数据及生存的相关性。
主要发现
- GR表达在非子宫内膜样肿瘤中较子宫内膜样肿瘤显著升高。
- GR表达与侵袭性疾病标志物及不良生存相关,单因素和多因素分析校正年龄、FIGO分期和组织学分级后均显著。
- 在激素受体阴性肿瘤亚组(雄激素受体、雌激素受体或孕激素受体缺失)中,GR表达与疾病特异性生存差高度显著相关。
- 从原发灶到转移灶GR表达总体升高,且多数转移灶表达GR。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucocorticoid receptor (GR) has emerged as an important steroid nuclear receptor in hormone dependent cancers, however few data are available regarding a potential role of GR in endometrial cancer. The aim of this study was to investigate expression of GR in primary and metastatic endometrial cancer lesions, and to assess the relationship between GR expression and clinical and histopathological variables and survival. METHODS: Expression of GR was investigated by IHC in 724 primary tumors and 289 metastatic lesions (from 135 patients), and correlations with clinical and histopathological data and survival were explored. RESULTS: Expression of GR was significantly increased in non-endometrioid tumors compared to endometrioid tumors, and was associated with markers of aggressive disease and poor survival both in univariate and multivariate analysis after correcting for age, FIGO stage and histologic grade. Within the subgroups of hormone receptor negative tumors (loss of androgen receptor, estrogen receptor or progesterone receptor) expression of GR was highly significantly associated with poor disease specific survival. There was an overall increase in GR expression from primary to metastatic lesions, and the majority of metastases expressed GR. CONCLUSION: GR expression in primary endometrial cancer is associated with aggressive disease and poor survival. The majority of metastatic endometrial cancer lesions express GR; therefore GR may represent a therapeutic target in the adjuvant therapy of poor prognosis early-stage as well as metastatic endometrial cancer.
引用
- Tangen IL, Veneris JT, Halle MK, et al. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017. PMID: 28927900. doi:10.1016/j.ygyno.2017.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。